News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
262,567 Results
Type
Article (13928)
Company Profile (226)
Press Release (248413)
Section
Business (79841)
Career Advice (162)
Deals (14773)
Drug Delivery (27)
Drug Development (50208)
Employer Resources (33)
FDA (5631)
Job Trends (5270)
News (146152)
Policy (10336)
Tag
Academia (936)
Africa (148)
Alabama (22)
Allergies (28)
Alliances (21621)
ALS (14)
Alzheimer's disease (668)
Antibody-drug conjugate (ADC) (27)
Approvals (5605)
Arizona (40)
Artificial intelligence (21)
Asia (16835)
Australia (2811)
Bankruptcy (98)
Best Places to Work (4419)
Biosimilars (16)
C2C Services and Suppliers (11319)
California (532)
Canada (346)
Cancer (101)
Career advice (145)
CAR-T (26)
Cell therapy (56)
China (27)
Clinical research (38710)
Collaboration (40)
Colorado (18)
COVID-19 (968)
Cystic fibrosis (56)
Data (15)
Diabetes (14)
Diagnostics (1261)
Drug pricing (18)
Duchenne muscular dystrophy (15)
Earnings (28152)
Employer resources (31)
Europe (35912)
Events (46130)
Executive appointments (19)
FDA (5652)
Florida (47)
Funding (27)
Gene editing (16)
Gene therapy (46)
GLP-1 (246)
Government (1102)
Healthcare (6782)
Hotbed/Location (189932)
Idaho (16)
Illinois (41)
Indiana (36)
Infectious disease (971)
Inflammatory bowel disease (75)
Interviews (16)
IPO (8499)
Job creations (897)
Job search strategy (140)
Kansas (49)
Layoffs (171)
Legal (1526)
Liver cancer (24)
Lung cancer (18)
Maryland (117)
Massachusetts (276)
Medical device (2663)
Medtech (2663)
Mergers & acquisitions (6209)
Metabolic disorders (81)
Neuroscience (725)
New Jersey (38)
New York (46)
NextGen Class of 2024 (2036)
Non-profit (911)
North Carolina (70)
Obesity (51)
Opinion (81)
Parkinson's disease (24)
Peanut (25)
Pennsylvania (22)
People (24725)
Phase I (13583)
Phase II (18008)
Phase III (11462)
Policy (17)
Postmarket research (846)
Preclinical (5750)
Rare diseases (71)
Real estate (1553)
Recruiting (14)
Regulatory (8033)
Research institute (967)
Resumes & cover letters (16)
Series A (16)
South America (216)
Startups (1979)
Texas (28)
United States (1520)
Vaccines (104)
Washington State (74)
Weight loss (42)
Date
Today (23)
Last 7 days (266)
Last 30 days (1099)
Last 365 days (22348)
2024 (12739)
2023 (22850)
2022 (27640)
2021 (28994)
2020 (24925)
2019 (16956)
2018 (12246)
2017 (14145)
2016 (12143)
2015 (14792)
2014 (10689)
2013 (7746)
2012 (7767)
2011 (7835)
2010 (7617)
262,567 Results for "avenue therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.
June 20, 2024
·
1 min read
Deals
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics, Inc. today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock.
April 24, 2024
·
7 min read
Business
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024.
May 15, 2024
·
11 min read
Deals
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Avenue Therapeutics, Inc. today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock.
April 29, 2024
·
7 min read
Business
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.
March 18, 2024
·
12 min read
Deals
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Avenue Therapeutics, Inc. today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.
March 15, 2024
·
4 min read
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Avenue Therapeutics, Inc. today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease, on Thursday, April 4, 2024 at 11:00am ET.
March 25, 2024
·
7 min read
Drug Development
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
Avenue Therapeutics, Inc. today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease.
May 16, 2024
·
10 min read
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
Avenue Therapeutics, Inc. today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on Thursday, January 18, 2024 at 10:00 a.m. EST.
January 11, 2024
·
4 min read
Deals
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
Avenue Therapeutics, Inc. today announced the entry into warrant exercise agreements with existing accredited investors for the immediate exercise of certain outstanding warrants to purchase an aggregate of 16.5 million shares of the Company’s common stock.
January 5, 2024
·
5 min read
1 of 26,257
Next